7 
clause similar to FIFRA and FDA rules has been offered, that 
additional consideration of registration for private industry is 
needed, and that public members and conflict of interest 
restrictions on IBCs causes concern. In addition, Commerce 
reported an interest by private industry in NIH/ORDA advice. 
Department of Transportation 
It was reported that a letter from DoT has been sent raising 
concern over Guideline language regarding shipment. DoT reports 
that it currently cannot regulate shipment of recombinant DNA 
molecules . 
Department of Justice 
The Department of Justice representative reported no comment on the 
Guidelines . 
P.S. Arms Control and Disarmament Agency 
No comments on the Guidelines were cited. 
Department of State 
No comment was made on the Guidelines; however, the question was 
raised over the possibility of the need to review a previous 
Committee decision on the need for an international convention on 
recombinant DNA research or commerce. It was agreed that the need 
for such a convention was unnecessary in the light of WHO 
Guidelines on the shipment of hazardous agents, the commonality of 
containment guidelines in many countries, and the NIH policy 
providing for control of this research it funds abroad. 
IV. Summary and Conclusion 
The proposed procedural changes in the Guidelines were summarized 
by Dr. Fredrickson. He noted that these procedures had been 
developed largely in response to agency comments received on the 
Guidelines. With no objections noted, the Committee approved the 
proposed procedures subject to review by the DHEW Committee that 
was created by the Secretary to conduct the Department's September 
15 hearing and advise the Secretary on the final Guidelines. 
Mr. Peter LiBassi, Office of General Counsel, serves as Chairman 
and Dr. Fredrickson serves as Vice-Chairman. It was agreed that 
there was a consensus among the Committee on the proposed 
procedures, and this message will be conveyed to the DHEW DNA 
Committee. 
[ 438 ] 
